Second, the levels of GM-CSF, LIF, OSM, phospho-STAT3(Tyr705), and phospho-STAT5(Tyr694) should be investigated in AML patients with IDH2/R140Q mutant and IDH2/WT to provide evidence for targeting phospho-STAT5(Tyr694), and phospho-STAT3(Tyr705) in the treatment of IDH2-mutated AML. This evidence concerns the gene LIF and acute myeloid leukemia.